TVTX — Travere Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1438533 ·
Last close
$51.10
Market Cap
$4.91B
52W High
$68.73
52W Low
$22.59
ADV30
2,086,610
Next earnings
2026-11-02

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 224,563,000 213,728,000 45,010,000 -52,337,000 848,229,000 123,542,000 825,645,000
Jun 2026 169,584,000 160,349,000 3,954,000 -34,797,000 799,360,000 117,735,000 774,838,000
Mar 2026 127,199,000 100,433,000 -36,915,000 -37,102,000 555,188,000 78,362,000 456,460,000
Dec 2025 129,689,000 127,136,000 -32,428,000 2,729,000 605,191,000 93,035,000 490,363,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$153,087,000
Investing CF
$-409,203,000
Financing CF
$245,688,000
CapEx
$-203,978,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.29
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,596,949,000
Inventory
$10,516,000
Receivables
$107,528,000
ST Investments
$348,276,000
EBIT TTM
$-150,850,000
Pretax Income TTM
$-159,720,000
Interest Exp TTM
$8,870,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$651,033,984
EBITDA
$32,403,000
Free Cash Flow
$-64,789,248
Enterprise Value
$4,905,547,776
Total Cash
$471,817,984
Total Debt
$616,155,008
Shares Out
95,992,155
Trailing EPS
$-1.67
Book Value
$0.24
ROE
-321.2%
ROA
-1.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 490,728,000 -62,824,000 -25,546,000 605,191,000 490,363,000 114,828,000 37,784,000
Dec 2024 233,175,000 -321,389,000 -321,545,000 594,125,000 535,048,000 59,077,000 -237,475,000
Dec 2023 145,238,000 -376,744,000 -111,399,000 788,913,000 588,103,000 200,810,000 -280,021,000
Dec 2022 109,460,000 -319,813,000 -278,482,000 672,585,000 629,734,000 42,851,000 -186,291,000

TTM Snapshot

Revenues TTM
$591,330,000
NetIncome TTM
$-43,464,000
OpCashFlow TTM
—
Assets (Latest)
$799,360,000
Forward EPS
$5.28

Max Pain — expiry 2027-01-15

max pain strike: $30.00 · spot: $50.24 · call oi: 13,290 · put oi: 3,385
Expected Move to 2027-01-15: ±$6.42 (12.79%) — implied range $43.82 – $56.67 · ATM straddle on $50.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
DNTH Dianthus Therapeutics, Inc. /DE/ $4.90B $86.98 —
ERAS Erasca, Inc. $4.87B $13.89 —
COGT Cogent Biosciences, Inc. $4.85B $27.85 —
PTCT PTC THERAPEUTICS, INC. $5.04B $60.36 —
LQDA Liquidia Corp $5.11B $56.73 —

News headlines (Yahoo Finance, 1h cache)

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-12 22:00 · Yahoo
Travere Crashed Into Its 200-Day Line And Then Reversed Higher; Here's Why
2026-11-03 21:36 · Yahoo
Travere Therapeutics to Participate at Upcoming Investor Conferences
2026-11-03 21:30 · Yahoo
Why Travere Therapeutics (TVTX) Could Be 34% Undervalued On Its Q3 Loss
2026-11-03 08:10 · Yahoo
Travere Therapeutics (TVTX) Stock Looks Fully Priced After Its 7x Run
2026-11-03 07:06 · Yahoo
What Could Travere Therapeutics (TVTX) New Biomarker Data Mean For IgA Nephropathy?
2026-11-03 06:14 · Yahoo
Travere: Q3 Earnings Snapshot
2026-11-03 04:37 · Yahoo
What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
2026-11-03 00:14 · Yahoo
Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings
2026-11-02 22:30 · Yahoo
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
2026-11-02 21:55 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.